Can a plant compound tame COVID-19's deadly inflammation?

NCT ID NCT04476953

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether fisetin, a natural compound found in fruits and vegetables, can reduce dangerous inflammation and improve oxygen levels in hospitalized COVID-19 patients. About 80 adults aged 60+ (or younger with certain health conditions) will receive either fisetin or a placebo for two days. The goal is to see if fisetin can prevent the disease from getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fisetin
What this could lead to: If it works, this could point toward a treatment that reduces severe inflammation and improves breathing in hospitalized COVID-19 patients.
What could go wrong: This is a small, early-phase pilot study with only 80 participants, so results may not be conclusive. The drug may not show benefit or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.